On 12 December 2017, orphan designation (EU/3/17/1951) was granted by the European Commission to Clinical Network Services (UK) Ltd, United Kingdom, for agammaglobulinaemia tyrosine kinase (also known as PRN1008) for the treatment of pemphigus.
The sponsorship was transferred to Clinical Network Services (NL) B.V., The Netherlands, in January 2019.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
Agammaglobulinaemia tyrosine kinase
|Disease / condition||
Treatment of pemphigus
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.